Advertisement Zila Responds To Intelident Litigation - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Zila Responds To Intelident Litigation

Intelident appears to be attempting to confuse shareholders, said the company

Zila has issued the following response to a complaint filed in the Delaware Court of Chancery by Intelident:

“Zila is disappointed that Intelident is using a litigation strategy to achieve its objectives. Intelident appears to be attempting to confuse shareholders with an offer that clearly fails to satisfy conditions necessary to consummate a transaction. Intelident was involved in litigation when it acquired Coast Dental. Zila will not comment on the litigation, but is confident that the Delaware court will reject Intelident’s claims, so that Zila can avoid bankruptcy and bring value to its shareholders. The Board continues to be prepared to review and act upon superior offers for the benefit of its shareholders in accordance with the exercise of its fiduciary duties.”

Earlier on July 10, 2009, Intelident had quoted to acquire all of Zila’s common stock for $0.42 per share, on which the board had concluded that the Intelident proposal is not superior to Zila’s existing agreement to be acquired by Tolmar.